Group 1: Company Overview and Business Focus - The company is focused on developing next-generation edge brain-machine interface algorithm chips and advancing mixed biometric and brain signal collaborative analysis [2] - The joint venture is currently in the preparation stage for business registration [2] Group 2: Performance Guidance and Targets - The company has set performance assessment targets for 2026 based on the 2025 restricted stock incentive plan and employee stock ownership plan [2] - Strategies to achieve growth include deepening technology applications, expanding market reach, enhancing brand influence, and increasing product and service competitiveness [2] Group 3: Incentive Plan and Acquisitions - The stock incentive plan specifies that the operating results of newly acquired companies will not be included in the performance assessment during the incentive period [3] - The impact of these acquisitions on the company's net profit and operating income will be calculated separately [3] Group 4: Competitive Advantages - The company leverages long-term accumulation in cognitive space computing and focuses on AI BioCV TinyML edge model development [3] - The integration of perception, analysis, and decision-making capabilities into edge devices establishes a solid technical foundation for wearable and scenario-based applications of non-invasive brain-machine interfaces [3] Group 5: Team Strengths and Market Position - The team has extensive experience in the industry, with a strong data accumulation in consumer scenarios and a stable performance indicator [3] - The founding and R&D team includes members from Silicon Valley and renowned U.S. institutions, covering multiple fields such as chip design and algorithm development [3] Group 6: Currency and Risk Management - The company has not yet adopted digital RMB for cross-border settlements, and foreign income constitutes a significant portion of its revenue [3] - To mitigate currency fluctuation risks, the company employs global supply chain strategies and local operations of subsidiaries, along with forward foreign exchange contracts [3]

Group 1: Company Performance and Goals - The company aims for a 15% growth in annual revenue or net profit attributable to the parent company, excluding non-recurring gains and losses [2] - Historically, the company's fourth-quarter performance has consistently outperformed other quarters, with expectations for stable growth in overseas markets [2] Group 2: Joint Venture and Business Development - The joint venture focuses on developing next-generation edge brain-machine interface algorithm chips and advancing mixed biometric and brain signal analysis [2] - The company is in the process of registering the joint venture, which aims to provide competitive practical brain-machine interface solutions for diverse global consumer groups and industries [2] Group 3: Future Investment and Acquisition Strategy - The company adopts a dual strategy of organic growth and external development, with the acquisition of 55% of Longzhiyuan being its first acquisition since going public [3] - Future investments and acquisitions will target projects that enhance the company's value [3] Group 4: Consumer Market Strategy - The company is committed to the "NGTeco" brand, focusing on the consumer market by integrating smart home, robotics, outdoor sports, and health care into a unified smart ecosystem [4] - The acquisition of Longzhiyuan is expected to expand the company's smart outdoor business and create synergies between products and technology [4] Group 5: Industry Trends and Market Potential - The brain-machine interface business is expected to grow significantly over the next two to three years, driven by technological advancements, demographic trends, and supportive policies [5] - The Chinese government has recognized brain-machine interfaces as a strategic future industry, marking it as a new economic growth point [5] Group 6: Technical Development Plans - The company currently focuses on non-invasive brain-machine interface technology, with potential future research into invasive brain-machine technologies as the field evolves [6]

Core Viewpoint - Entropy Technology (301330) is actively pursuing strategic acquisitions and expanding its brain-computer interface (BCI) technology, focusing on education, healthcare, and elderly care applications, while maintaining a strong cash flow and exploring further investment opportunities [2][3][4]. Group 1: Acquisition and Financial Performance - Entropy Technology signed a "Letter of Intent" with Longzhiyuan on October 17, 2025, to acquire a 55% stake, with completion expected by the end of November [2]. - For the first three quarters of 2025, the company reported a main revenue of 1.401 billion yuan, a year-on-year decrease of 0.68%, while net profit attributable to shareholders increased by 6.24% to 128 million yuan [7]. Group 2: Brain-Computer Interface Development - The company is focusing on BCI technology in three core application areas: education, healthcare, and elderly care, utilizing multi-modal data fusion technology for product development [3]. - A prototype for the BCI business is expected to be launched by March 2026, and a strategic partnership with NeuroSky has been established to enhance BCI and multi-modal biometric technology integration [3]. Group 3: Market Position and Strategy - The BCI business overlaps with existing clients in healthcare and education, while also targeting new customer segments in consumer electronics, industry, and research [5]. - The company emphasizes a dual strategy of organic growth and external development, with the acquisition of Longzhiyuan being its first since going public [4].